People: Peregrine Pharmaceuticals Inc (PPHM.A)

PPHM.A on American Stock Exchange

1.53USD
17 May 2013
Price Change (% chg)

$0.02 (+1.26%)
Prev Close
$1.51
Open
$1.56
Day's High
$1.57
Day's Low
$1.51
Volume
25,888
Avg. Vol
--
52-wk High
$1.68
52-wk Low
$1.27

Search Stocks

Summary

Name Age Since Current Position

Carlton Johnson

 52 2010 Independent Chairman of the Board

Steven King

 48 2003 President, Chief Executive Officer, Director

Paul Lytle

 44 2002 Chief Financial Officer, Corporate Secretary

Mark Ziebell

 48 2012 Vice President, General Counsel

Shelley Fussey

 46 2005 Vice President - Intellectual Property

Jeffrey Masten

 51 2011 Vice President - Quality

Joseph Shan

 39 2009 Vice President - Clinical & Regulatory Affairs

David Pohl

 75 2004 Independent Director

Eric Swartz

 56 1999 Independent Director
» Insider Trading

Biographies

Name Description

Carlton Johnson

 Mr. Carlton M. Johnson, Jr., is Independent Chairman of the Board of Peregrine Pharmaceuticals Inc. Mr. Johnson has served as a Director since November 1999 and was appointed Chairman of the Board on October 22, 2010. Mr. Johnson is in-house legal counsel for Roswell Capital Partners, LLC, a position he has held since June 1996. Mr. Johnson has been admitted to the practice of law in Alabama since 1986, Florida since 1982 and Georgia since 1997. He has been a shareholder in the Pensacola, Florida AV- rated law firm of Smith, Sauer, DeMaria, Johnson and was President-Elect of the 500 member Escambia-Santa Rosa Bar Association. He also served on the Florida Bar Young Lawyers Division Board of Governors. Mr. Johnson earned a degree in History/Political Science at Auburn University and Juris Doctor at Samford University - Cumberland School of Law. Mr. Johnson also serves on the board of Patriot Scientific Corporation, and formerly served on the boards of CryoPort, Inc. (ceased in May 2012), and Ecotality, Inc. (ceased in March 2012). The Board of Directors concluded that Mr. Johnson should serve as a director in light of the public company finance experience that he has obtained through serving on the boards and audit committees of Patriot Scientific Corporation, CryoPort, Inc. and Ecotality, Inc.

Steven King

 Mr. Steven W. King is President, Chief Executive Officer, Director of Peregrine Pharmaceuticals Inc. Mr. King has served as President and Chief Executive Officer since March 2003 and a member of the Board of Directors since October 2003. From August 2002 to March 2003, Mr. King served as Chief Operating Officer and from February 2000 to August 2002 served as Vice President of Technology and Product Development. Mr. King joined Peregrine in 1997 as Director of Research and Development. Additionally, Mr. King was responsible for launching wholly-owned biomanufacturing subsidiary, Avid Bioservices, Inc., in 2002, for which he serves as President. Mr. King was previously employed at Vascular Targeting Technologies, Inc., which was acquired by Peregrine in 1997. Mr. King previously worked at the University of Texas Southwestern Medical Center with Dr. Philip Thorpe, the inventor of Phosphatidylserine (PS)-targeting antibody and VTA technology platforms and is co-inventor on over 40 U.S. and foreign patents and patent applications in the Vascular Targeting Agent field. Mr. King received his Bachelor’s and Master’s degrees from Texas Tech University in Cell and Molecular Biology.

Paul Lytle

 Mr. Paul J. Lytle is Chief Financial Officer, Corporate Secretary of Peregrine Pharmaceuticals Inc. He has over 19 years of finance and accounting experience. Mr. Lytle oversees various functions, including finance and accounting, financial reporting, Corporate Governance, investor relations, human resources and information technology. Mr. Lytle started with Peregrine in March 1997 as Corporate Controller and has held positions of increasing responsibility at the Company. Mr. Lytle was promoted to Vice President of Finance and Accounting and was elected as the Company’s Corporate Secretary in 2000. Prior to joining Peregrine, Mr. Lytle worked for Deloitte & Touche LLP. Mr. Lytle holds a B.S. in Business Administration from the California State University at Long Beach and is a certified public accountant in the State of California and a member of the American Institute of Certified Public Accountants.

Mark Ziebell

 Mr. Mark R. Ziebell has been appointed as Vice President, General Counsel of Peregrine Pharmaceuticals, Inc. For the past seventeen years, Mr. Ziebell has practiced law with an emphasis in securities, mergers and acquisitions and general corporate law, representing companies in a broad range of industries including the biopharmaceutical and technology sectors. Prior to joining the Company, from March 2004 to June 2012, Mr. Ziebell practiced law in the Costa Mesa, California office of Snell & Wilmer L.L.P., where he was a partner during the past five years. Founded in 1938, Snell & Wilmer is a full-service business law firm with more than 400 attorneys practicing in nine locations throughout the western United States and in Mexico. Prior to March 2004, Mr. Ziebell practiced law at the firm of Falk, Shaff & Ziebell, LLP, in Irvine, California, Graham & James, LLP, in Los Angeles, California and Berliner Cohen, in San Jose, California. Mr. Ziebell earned his Juris Doctorate from the University of San Francisco, School of Law in 1994 and his BA in Accounting from the University of San Francisco in 1985.

Shelley Fussey

 Dr. Shelley P.M. Fussey, Ph.D., is Vice President - Intellectual Property of Peregrine Pharmaceuticals Inc. Dr. Fussey plays a key role in U.S. and international patenting, patent analysis and patent defense. Dr. Fussey's includes patent strategy for technologies developed both in-house and in-licensed from universities. She has broad experience in intellectual property consulting for areas including cancer treatment, immunology, and antiviral technology, as well as other areas central to pharmaceutical and biotechnology drug development. Prior to joining Peregrine, Dr. Fussey worked for the law firms of Williams, Morgan & Amerson and Arnold, White and Durkee. She holds a Ph.D. in Biochemistry and a B.Sc. in Biochemistry with First Class Honours (Summa Cum Laude) from the University of Newcastle upon Tyne, U.K.

Jeffrey Masten

 Mr. Jeffrey L. Masten is Vice President - Quality of Peregrine Pharmaceuticals Inc. Mr. Masten is responsible for the overall quality assurance program for both Peregrine and its wholly-owned subsidiary, Avid Bioservices, Inc. Prior to joining Peregrine, Mr. Masten has served as Senior Director, Head of Quality Assurance at two Genentech manufacturing sites. At Genentech from 2002 to 2011, he designed and implemented quality programs, spanning the bulk formulation and aseptic processing and fill/finish of biologics, and led regulatory inspections from domestic and international agencies. Prior to Genentech, he was Director, Quality Operations for Aventis Behring, which was acquired by CLS Behring. He began his 30-year career in quality assurance at Eli Lilly and Company. Mr. Masten earned a Master of Business Administration from the University of Notre Dame, a Bachelor of Science from Salisbury University, and completed chemistry and pharmacology graduate-level courses at Indiana University and Butler University, respectively.

Joseph Shan

 Mr. Joseph S. Shan is Vice President - Clinical & Regulatory Affairs of Peregrine Pharmaceuticals Inc. He is responsible for the design and execution of clinical trials and overseeing regulatory submissions. Since joining Peregrine in 2000, Mr. Shan has been instrumental in advancing the clinical development of the Company's bavituximab and Cotara® antibody products. Prior to joining Peregrine, Mr. Shan held positions of increasing responsibility in clinical and regulatory affairs at Edwards Lifesciences (formerly Baxter Healthcare Corporation) and Sulzer Medica. Mr. Shan received his B.S. degree in Physiological Sciences from the University of California, Los Angeles and his M.P.H. degree from the George Washington University in Washington, D.C. He is a member of the American Society of Clinical Oncology, the Association of Clinical Research Professionals and the Regulatory Affairs Professionals Society.

David Pohl

 Mr. David H. Pohl is Independent Director of Peregrine Pharmaceuticals Inc. He is currently Chairman of the Board of Wellness.com, Inc., a privately held Internet-based health and wellness enterprise. He was previously a member of the Board of Directors of Patriot Scientific Corporation from 2001 through 2008, and served as Chairman of the Board and CEO of that publicly traded company from 2005 through 2007. He is also Of Counsel with the law firm of Herold & Sager in Encinitas, California. Mr. Pohl was in the private practice of law, counseling business clients from 1997 to 2005, and serving as Special Counsel to the Ohio Attorney General for entrepreneurial investments by state employee pension funds from 1995 to 1996. Previously, he was a Senior Attorney with Jones Day Reavis & Pogue, a U.S. law firm, and held positions as a Senior Officer and General Counsel in financial services corporations with over $1 billion in assets under management. In addition, Mr. Pohl is a member of the Corporate Directors Forum of San Diego, the Intellectual Property Law and Business Law Sections of the State Bar of California, has served as a member of the Board of Governors of the Corporate Counsel Section of the Ohio State Bar Association, and is an Emeritus member of the Board of Directors of the American Financial Services Association, Washington, D.C. Mr. Pohl earned a Juris Doctor degree from The Ohio State University College of Law, and also holds a B.S. in Administrative Sciences from Ohio State. The Board of Directors concluded that Mr. Pohl should serve as a director in light of the corporate governance experience that he has obtained through serving on the boards of Patriot Scientific Corporation and Wellness.com.

Eric Swartz

 Mr. Eric S. Swartz is Independent Director of Peregrine Pharmaceuticals Inc. With 29 years of experience in the securities business, Mr. Swartz is the founder and President of Roswell Capital Partners, LLC since 2004 and was the founder and former President of Equiplace Securities, LLC and Swartz Investments, LLC. From 1988 to 1993, Mr. Swartz was a Vice President at Bear Stearns & Co. where he specialized in foreign institutional equity investments in U.S. securities. Previously, Mr. Swartz was a Vice President with Oppenheimer & Co., where he was involved in overseas placements of equity and debt for institutions in Germany, Austria, Switzerland, France, Australia, and New Zealand.

Basic Compensation

Name Fiscal Year Total

Carlton Johnson

 --

Steven King

 1,160,550

Paul Lytle

 666,729

Mark Ziebell

 --

Shelley Fussey

 478,518

Jeffrey Masten

 831,688

Joseph Shan

 569,708

David Pohl

 --

Eric Swartz

 --
As Of 29 Apr 2012

Options Compensation

Name Options Value

Carlton Johnson

 0 0

Steven King

 1,257,499 516,625

Paul Lytle

 880,833 234,025

Mark Ziebell

 0 0

Shelley Fussey

 0 0

Jeffrey Masten

 0 0

Joseph Shan

 0 0

David Pohl

 0 0

Eric Swartz

 0 0

Insider Trading

Name Shares Traded Price

FUSSEY SHELLEY P M

 17,980 $0.39

KING STEVEN W

 11,000 $0.39

LYTLE PAUL J

 20,885 $0.39

FUSSEY SHELLEY P M

 12,498 $0.40

MASTEN JEFFREY L

 12,498 $0.40

LYTLE PAUL J

 12,498 $0.40

KING STEVEN W

 10,726 $0.40

SWARTZ ERIC S

 16,000 $0.62

LYTLE PAUL J

 5,122 $0.89

KING STEVEN W

 4,804 $0.89

FUSSEY SHELLEY P M

 5,122 $0.89

SHAN JOSEPH S

 5,000 $0.00

KING STEVEN W

 14,000 $0.00

LYTLE PAUL J

 9,000 $0.00

FUSSEY SHELLEY P M

 5,000 $0.00
» Full list on Insider Trading
Search Stocks